Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/12—Ketones
  • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• the present invention relates to therapeutic interventions for endoplasmic reticulum stress (ER stress). More specifically, the present invention relates to the potential of garcinoi as a therapeutic agent for acute ER stress as a transcription attenuator and transcription recovery agent.
• Endoplasmic reticulum plays a critical role in cellular stress responses by the synthesis and processing of secretory and membrane proteins (Umut O ''zcan et al., (2004), Endoplasmic Reticulum Stress Links Obesity, Insulin Action, and Type 2 Diabetes, Science; 306(5695):457-61).
• Molecular chaperones present in the ER, facilitate proper protein folding, maintaining them in a folded state, and preventing protein aggregate formation (Lee AS., (2005), The ER chaperoue and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress. Methods; 35(4)'.373-381).
• the ER lumen maintains a unique environment to establish a balance between the ER protein load and the capacity to handle this load.
• Physiological or pathological processes that disturb ER homeostasis cause ER stress and activate a set of signaling pathways known as the Unfolded Protein Response (UPR) to cope up with the stress.
• URR Unfolded Protein Response
• the initial objective of the UPR is to re-establish homeostasis and alleviate ER stress through two mechanisms: (a) increasing folding capacity via expression of protein- folding chaperones and (b) downregulation of ER protein by inhibiting general protein translation and promoting the degradation of mis folded proteins. Under prolonged or severe stress, the UPR initiates apoptosis and cell death. UPR-mediated cell death may contribute to the pathogenesis of many diseases including cancer, type 2 diabetes, ueurodegeneration, and atherosclerosis (Tabas and Ron (2011), Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol.
• PKR ER kinase
• ATF6 activated transcription factor 6
• IRE'l Inositoi-requirmg enzyme 1
• IRE1 has a cytoplasmic endoribonuciease domain, which, upon activation, splices and enables the translation of the mRNA encoding X-box binding protein- 1 (XBPl).
• Spliced XBPl is a transcription factor that induces many essential UPR genes that increase ER folding capacity and expand ER membrane surface area.
• Activated PERK phosphorylates eukaryotic translation initiation factor 2 alpha (eIF2a), which results in global translational attenuation and reduced ER protein load.
• Phosphorylated eEF2a promotes the translation of ATF4 (activating transcription factor- ⁇ 1), which induces the UPR effector CHOP which triggers apoptosis through a number of mechanisms.
• ATF6 translocates to the Golgi complex, where it gets cleaved by site 1 and site 2 proteases. The resultant transcription factor then migrates to the nucleus to increase the expression of ER chaperones such as Grp78.
• Therapeutic interventions may be useful in either phases or in one of the phases.
• Evidence of such therapeutic interventions thus forms the corner stone for the management of ER stress.
• Garcinol as an apoptotic signalling agent in ER stress has been reported by Cheng et al, "Garcinol inhibits cell growth in hepatocellular carcinoma Hep3B cells through induction of ROS-dependent apoptosis", Food Funct. 2010 Dec;l(3):301-7.
• Garcinol's role in apoptotic signalling through the activation of DNA damage-inducibie gene 153 (GADD I53) has been reported in this piece of technical literature.
• the present invention discloses the ability of garcinoi for the therapeutic management of ER stress. More specifically; the invention discloses the ability of garcinoi in decreasing ER stress and mitigating toxicity by reducing protein aggregation and decreasing expression of ER stress markers SXBP, GRP78 and ATF4, which indicates translational attenuation and recovery in hyperglycemia, paracetamol, alcohol, thapsigargin and high fat diet induced toxicity models.
• Fig. 1 is the graphical representation of protection against glucose induced toxicity in pancreatic beta cell line by garcinoi.
• Fig, 2 is a flow cytometric image showing the reduction in protein aggregation and reduction in ER stress garcinoi in Min6 pancreatic beta cells (glucose induced toxicity).
• Fig. 3 is a graphical representation showing dose dependant reduction in glucose in serum of mice supplemented with garcinoi (high fat induced diabetic condition in mice).
• Fig. 4 is a graphical representation showing decrease in the expression of ER stress markers in pancreas of animals supplemented with garcinoi (high fat induced diabetic condition in mice).
• Fig. 5a is a graphical representation showing percentage hepatoprotection by garcinoi in paracetamol induced liver toxicity (Prophylactic) in study animals.
• Fig. 5b is a graphical representation showing percentage hepatoprotection by garcinoi in paracetamol induced liver toxicity (Therapeutic) in study animals.
• Fig. 6 is a graphical representation showing percentage hepatoprotection by garcinoi in alcohol induced liver toxicity in HepG2 Cells
• Fig. 7a is a graphical representation showing percentage reduction in protein aggregation by garcinoi estimated by means thioflavin staining in thapsigargin induced human liver cells, US - unstressed cells, TG-Thapsigargin, G5, G10 - Garcinoi 5 and 10 ug/ml respectively, PBA: phenyl butyric acid ⁇ positive control)
• Fig. 7b is the flow cytometric image showing percentage reduction in protein aggregation by garcinoi estimated by means thioflavin staining in thapsigargin induced human liver cells.
• Fig. 7c is a graphical representation showing percentage reduction in protein aggregation by garcinoi estimated by means thioflavin staining in thapsigargin induced primary mouse hepatocytes.
• Fig. 8 is a graphical representation showing decrease in the expression of ER stress markers by garcinoi in hepatocytes treated with thapsigargin. TG-Thapsigargin, G5, G10 - Garcinoi 5 and 10 ug/ml respectively , PBA: phenyl butyric acid ( positive control).
• Fig. 9 is a graphical representation showing dose dependant decrease in liver weight of animals by garcinoi in animals administered with high fat diet.
• Fig. 10 is a graphical representation showing decrease in the expression of ER stress markers in pancrease of high fat diet administered animals supplemented with garcinoi.
• Fig. 11a is a graphical representation showing decrease in the expression of ER stress markers in adipocytes treated with thapsigargin.
• PBA phenyl butyric acid (positive control).
• Fig. 11b is a graphical representation showing decrease in the expression of ER stress markers in fat pads of high fat diet administered animals supplemented with garcinoi.
• the present invention relates to a method of treating endoplasmic reticulum stress in mammalian cells characterised by accumulation of unfolded or misfolded cellular protein transcripts, said method comprising step of treating said mammalian cells with effective concentrations of garcinoi to bring about effects of attenuating the accumulation of said unfolded or misfolded protein transcripts.
• the effective concentration of garcinol is 2 - 10 ⁇ g/ml.
• the mammalian cells are preferably human cells.
• the inventions disclose a method for reducing endoplasmic reticulum stress and related toxicity in mammals, said method comprising step of administering effective concentration of garcinol to said mammals to bring about a reduction in the toxicity and endoplasmic reticulum stress markers.
• ER stress is present in clinical conditions selected from the group consisting of, but not limited to, metabolic syndrome, diabetes, artheroscierosis, neurodegenerative disorders likes Alzheimer's disease and Parkinson's disease, alcoholic and non-alcoholic hepatic steatosis, cancer, viral infections, hyperglycemia, drug induced toxicity and obesity.
• the markers of ER stress are selected from the group consisting of spliced x-box DNA binding protein (SXBP), activating transcription faetor-4 (ATF-4) and glucose- regulated protein 78 (GRP78).
• SXBP spliced x-box DNA binding protein
• ATF-4 activating transcription faetor-4
• GFP78 glucose- regulated protein 78
• the mammal is human.
• the effective concentration of garcinol is 0,1 - 5 mg/kg body weight.
• garcinol is formulated in a composition along with phaimaceutieally/nutraceutically acceptable exeipients, adjuvants, diluents or carriers and administered orally in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies and eatables.
• the present invention relates to a method of therapeutic management of endoplasmic reticulum stress induced metabolic syndrome, said method comprising step of administering effective concentrations of garcinol to said mammals to bring about effects of attenuating the accumulation of said unfolded or misfolded protein transcripts leading to symptoms of metabolic syndrome.
• metabolic syndrome is present in clinical conditions selected from the group consisting of diabetes, artheroscierosis, neurodegenerative disorders likes Alzheimer's disease and Parkinson's disease, alcoholic and non-alcoholic hepatic steatosis, cancer, viral infections, hyperglycemia, drug induced toxicity and obesity.
• the mammal is human.
• the effective concentration of garcinol is 0.1 - 5 mg/kg body weight.
• garcinol is formulated in a composition along with pharmaceutically/nutraceutically acceptable exeipients, adjuvants, diluents or carriers and administered orally in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies and eatables.
• Cells were maintained in DMEM containing 25 mM glucose with 10% heat-inactivated fetal calf serum with antibiotics at 37°C and 5% C02. When the cells were 70-80% confluent, they were trypsinized, washed and seeded in 96 well plates at a density of 5x103 cells per well. Stress was induced by Thapsigargin(luM) for 4 hours, glucose (50 and 100 mM) and alcohol (1000mM) or paracetamol (4mM) for 72 hours. Garcinol was added along with stressor as prophylactic treatment. As a therapeutic treatment, cells were exposed to stress agent 24 hours following which Garcinol was added to the ceils. Protection was assessed by SRB assay after 72 hours of treatment
• mice C57/BL6 mice, 6-8 weeks of age and 8 animals/Group were used for the study. Animals were housed under standard laboratory conditions, air-conditioned with adequate fresh air supply (12 - 15 Air changes per hour), room temperature 20.2 - 23.5°C and relative humidity 58 64% with 12 hours fluorescent light and 12 hours dark cycle. The temperature and relative humidity was recorded once daily.
• [Para036] Feed The animals were fed with Normal diet (9kcaJ / day) and High fat diet (50kcal / day) throughout the acclimatization and experimental period. Water was provided along with High Fat Diet to the animals throughout the acclimatization and experimental period. Water from water filter cum purifier was provided in animal feeding bottle with stainless steel sipper tubes. Garcinol was administered to the animals along with the high fat diet. The dosage calculation from animals to humans as described by Regan-Shaw et al, (2007) Dose translation from animal to human studies revisited FASEB J. 22, 659-661 was used as reference.
• the CPCSEA approval number for the present study is SAC/IAEC/BC/2017/IP.-001.
• RNA was extracted using the Trizol method. Extracted RNA was treated with DNAse I to remove any contaminating DNA and again extracted using phenol: chloroform: isoamyl alcohol extraction (24:25:1). Quality of RNA was determined by checking the absorbance at 260/280 nm using a Nanodrop (Thermo)
• RNA was taken for cDNA synthesis using Superscript III First-Strand Synthesis System (Life Technologies). Quantitative RT-PCR analysis was performed to determine the expression of brown fat specific genes in Roche Light cycler 96 using SYBR Green master mix (Thermo Scientific), ⁇ actin was used as a house keeping gene The relative RNA abundance of genes associated with ER stress were normalized to the housekeeping ⁇ actin gene and expressed as delta delta CT (equivalent to fold change transformed by Lo.g2).
• IRE la phosophoiyiation levels can be assessed by measuring spliced XBP-1 product by RT PGR.
• PERK activation is measured by its phosphorylation levels or by measuring the ATF4 mRNA levels. Activation of ATF4 leads to increased transcription of a network of genes, including those encoding ER chaperones, such as BiP GRP78.
• Thioflavin T (ThT) is a small molecule with fluorescence properties that has been shown to bind selectively to protein aggregates and can be analysed by Flow cytometry
• Primer sequence The primers used for the determining the expression of ER stress specific genes are given in table 1
• pancreatic beta cells Under high glucose concentration ER stress is induced in pancreatic beta cells in vitro. These cells are grown in 5-1 OmM of Glucose, as the glucose concentration increases, the cells are stressed and ultimately undergo apoptosis at higher concentration.
• Gareinol treatment reduced the toxicity induced by Hyperglycemia in a dose dependent manner with an effect comparable to Metformin (100 uM) (Fig, 1), there by conferring Protection against Glucose induced Toxicity in Pancreatic Beta cell line . Gareinol treatment also redueed the protein aggregation induced by high concentration of Glucose in pancreatic cells (Fig, 2), and reducing the ER stress.
• Gareinol also conferred protection: against high fat induced pancreatic toxicity and serum glucose levels in mice. Gareinol reduced the serum glucose levels significantly (Fig, 3) suggesting it can be helpful in preventing obesity induced diabetes.
• the relative expression of ER stress markers were up regulated in pancreas of animals kept on high fat diet compared to control animals on chow diet feed. Gareinol treatment reduced the ER stress markers in FIFO fed animals (Fig. 4).
• Untreated cells were used as control and Phenyl butyric acid (PBA) was used as positive control.
• Treated and untreated cells were analysed by Flow cytometry and RT PGR.
• Garcinol significantly reduced protein aggregation in human liver cells (Fig. 7a and 7b) by 44.4% and in primary mouse hepatocytes (Fig. 7c) by 70.4% at a concentration of 10 ⁇ g/ml.
• Garcinol also reduced the expression of ER stress markers sXBP 1 and GRP78 (Fig. 8) indicating that garcinol is effective in reducing ER stress resulting due to increased protein aggregation.
• Garcinol reduced the liver weight significantly in high fat induced liver toxicity in mice (Fig. 9) suggesting it may be helpful in preventing obesity induced fatty liver.
• the expression of marker of ER stress - SXBP, GRP78 and ATF4 were also significantly reduced by garcinol in the high fat induced liver toxicity (Fig. 10) in mice model suggesting its use as a liver protection agent.
• Garcinol significantly decreased the expression of stress markers - SXBP, GRP78 and ATF4 in both the adipocytes (Fig. 11a) and in the fat pads (Fig. lib), indicating that Garcinol is effective in reducing the ER stress in High fat diet induced stress in adipose tissue of mice and reduces adipogenesis and obesity in mice.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Diabetes (AREA)
• Biomedical Technology (AREA)
• Epidemiology (AREA)
• Gastroenterology & Hepatology (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Emergency Medicine (AREA)
• Vascular Medicine (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Urology & Nephrology (AREA)
• Endocrinology (AREA)
• Psychiatry (AREA)
• Hospice & Palliative Care (AREA)
• Virology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Child & Adolescent Psychology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicinal Preparation (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (1)

Family

ID=64691689

Family Applications (1)

Country Status (7)

Cited By (1)

Families Citing this family (1)

Citations (5)

Family Cites Families (7)

• 2018
  • 2018-06-22 KR KR1020197038408A patent/KR20200011492A/ko not_active Ceased
  • 2018-06-22 WO PCT/US2018/038950 patent/WO2018237243A1/en not_active Ceased
  • 2018-06-22 JP JP2019570406A patent/JP2020525425A/ja active Pending
  • 2018-06-22 AU AU2018290320A patent/AU2018290320A1/en not_active Abandoned
  • 2018-06-22 EP EP18821067.8A patent/EP3614846A4/en not_active Withdrawn
  • 2018-06-22 US US16/015,503 patent/US20180369166A1/en not_active Abandoned
  • 2018-06-22 CA CA3065332A patent/CA3065332A1/en active Pending

Patent Citations (5)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events